Metabolic Activity by 18F-FDG-PET/CT Is Prognostic for Stage I and II Pancreatic Cancer
Metabolic Activity by 18F-FDG-PET/CT Is Prognostic for Stage I and II Pancreatic Cancer
复制标题
DOI：
10.1097/rlu.0000000000001098
复制
发表时间：
2016-03-01
影响因子：
10.6
通讯作者：
Malafa, Mokenge P.
中科院分区：
文献类型：
--
作者：
Pimiento, Jose M.;Davis-Yadley, Ashley H.;Malafa, Mokenge P.
目的：PET上F-18-FDG摄取所定义的代谢活性是多种恶性肿瘤的预后标志物;然而，还没有研究探讨FDG PET显像在I期和II期胰腺癌中的预后价值。我们研究的价值PET FDG摄取在早期胰腺癌patients.MethodsWe确定患者与早期胰腺癌（I-II）谁进行了FDG PET扫描作为其术前评估的一部分。根据原发肿瘤标准摄取值（SUVmax）的中位数将患者分为高或低FDG摄取组。我们的主要终点是总生存期（OS）和无复发生存期（RFS）。Kaplan-Meier估计用于生存分析。病理资料进行比较，使用Fisher精确和卡方（2）test.Results105例被确定：51例低FDG摄取和54例高FDG摄取。85名患者（81%）有PET avid肿瘤，而20名（19%）患者没有。高FDG摄取与病理分期相关（P = 0.012）。低FDG摄取患者的中位OS显著优于高FDG摄取患者（28个月vs. 16个月; P = 0.036）。低FDG摄取患者的中位RFS明显长于高FDG摄取患者（14与12个月; P = 0.049）。结论I期和II期胰腺癌患者PET扫描中FDG摄取低与OS和RFS改善相关。这支持了葡萄糖代谢途径在胰腺癌生物学中很重要的概念，并且PET扫描活性可以用作胰腺切除术后的预后生物标志物。
PurposeMetabolic activity, as defined by F-18-FDG uptake on PET, is a prognostic marker for multiple malignancies; however, no study has examined the prognostic value of imaging with FDG PET in stage I and II pancreatic cancer. We examined the value of PET FDG uptake in early-stage pancreatic cancer patients.MethodsWe identified patients with early-stage pancreatic cancer (I-II) who had FDG PET scan performed as part of their preoperative evaluation. The patients were divided into either high or low FDG uptake according to the median primary tumor standard uptake value (SUVmax). Our primary end points were overall survival (OS) and recurrence-free survival (RFS). Kaplan-Meier estimate was used for survival analysis. Pathologic data were compared using the Fisher exact and chi(2) tests.ResultsOne hundred five patients were identified: 51 patients with low FDG uptake and 54 patients with high FDG uptake. Eighty-five patients (81%) had PET avid tumors, whereas 20 (19%) patients did not. High FDG uptake correlated with pathologic stage (P = 0.012). Patients with low FDG uptake had significantly better median OS than patients with high FDG uptake (28 vs. 16 months; P = 0.036). Patients with low-FDG uptake had significantly longer median RFS than patients with high FDG uptake (14 vs. 12 months; P = 0.049).ConclusionsLow FDG uptake in PET scans in patients with stage I and II pancreatic cancer correlates with improved OS and RFS. This supports the concept that glucose metabolic pathways are important in pancreatic cancer biology and that PET scan activity can be used as a prognostic biomarker after pancreatectomy.